Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Webcast Interview with CEO

19th Jul 2010 07:00

RNS Number : 5036P
ABCAM Plc
19 July 2010
 



For immediate release

19 July 2010

 

 

RNS REACH

 

ABCAM PLC

("Abcam" or "the Company")

 

Webcast interview with Jonathan Milner, CEO

 

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce that a webcast interview with Jonathan Milner, the Company's Chief Executive Officer, is ready to view at the London Stock Exchange website:

 

www.londonstockexchange.com/growing-company-interviews

 

In the interview, Dr Milner discusses the dynamics of the antibody marketplace and gives an insight into Abcam's history and operations, highlighting the importance of the internet to the Company's business model.

 

The interview marks the beginning of a series of webcasts hosted by the London Stock Exchange entitled Growing Company Interviews. The interviews are designed to give investors a better understanding of selected companies quoted on the London market.

 

 

For further information please contact:

 

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

 

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court / Stasa Filiplic

 

 

 

Notes for editors

 

About Abcam plc

 

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies, from over 250 suppliers. Abcam employs 270 staff in its four operating companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZQLFFBDFEBBV

Related Shares:

ABC.L
FTSE 100 Latest
Value8,850.63
Change-34.29